Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana Prior Auth & Notification List | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHumanaPolicy N/A

    Humana Dual Fully Integrated Illinois prior authorization and notification list (medications/services)

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization and notification requirements for medications (including professionally administered drugs) and certain services for Humana Dual Fully Integrated Illinois HMO D‑SNP and related Humana Medicare Advantage plans; affects participating providers and delegated networks submitting authorization requests.

    Policy Summary
    PayerHumana
    PolicyPrior authorization and notification list — Humana Dual Fully Integrated Illinois
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionInitiate prior authorization via CoverMyMeds, by phone at 866-461-7273 (TTY: 711), or by fax to 888-447-3430 and include required patient, billing and clinical information.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90+listed medications (document partial)
    3ways to initiate prior authorization
    90 daysactive treatment exception
    NDC reqHCPCS/NDC requirement noted

    Prior Authorization and Notification Coverage Criteria

    Prior authorization / notification list (partial)

    Medications listed below require prior authorization or notification as indicated. Providers must use the listed billing codes when submitting claims and follow the submission instructions and special notations. Symbols: * New preauthorization requirement; † New-to-market drug addition; ‡ HCPCS shared code — corresponding NDC must be billed on all claims; ** Step therapy required through a Humana-preferred drug as part of preauthorization; †† Preauthorization requests for transplant-related products are reviewed by the Humana National Transplant Network.

    Herceptin Hylecta — trastuzumab and hyaluronidase-oysk. Billing codes = J9356.
    Hercessi IV — trastuzumab-strf. Billing codes = Q5146.
    Herzuma — trastuzumab-pkrb. Billing codes = Q5113.
    Hizentra — immune globulin. Billing codes = J1559.
    Hyalgan ** ‡ — sodium hyaluronate. Billing codes = J7321.
    Hymovis ** ‡ — sodium hyaluronate. Billing codes = J7322.
    Hymovis ONE ** ‡ — hyaluronate. Billing codes = C9399, J3490.
    Hyqvia ** — immune globulin. Billing codes = J1575.
    Ilaris — canakinumab. Billing codes = J0638.
    Ilumya ** — tildrakizumab-asmn. Billing codes = J3245.
    Iluvien — fluocinolone acetonide. Billing codes = J7313.
    Imaavy ** — nipocalimab-aahu. Billing codes = J9256.
    Imdelltra — tarlatamab-dlle. Billing codes = J9026.
    Imfinzi ** — durvalumab. Billing codes = J9173.
    Imjudo ** — tremelimumab-actl. Billing codes = J9347.
    Imlygic — talimogene laherparepvec. Billing codes = J9325.
    Imuldosa IV ** ‡ — ustekinumab-srlf. Billing codes = Q5098.
    Inflectra — infliximab-dyyb. Billing codes = Q5103.
    Infliximab — infliximab. Billing codes = J1745.
    Injectafer ** — ferric carboxymaltose. Billing codes = J1439.
    Inlexzo intravesical system — gemcitabine. Billing codes = J9183.
    Oxlumo — lumasiran. Billing codes = J0224.
    Ozurdex — dexamethasone intravitreal implant. Billing codes = J7312.
    Paclitaxel protein-bound ** ‡. Billing codes = J9264.
    Padcev — enfortumab vedotin-ejfv. Billing codes = J9177.
    Palynziq ‡ — pegvaliase-pqpz. Billing codes = C9399, J3490, J3590.
    Panhematin — hemin. Billing codes = J1640.
    Panzyga ** — immune globulin. Billing codes = J1576.
    Papzimeos — zopapogene imadenovec-drba. Billing codes = J3404.
    Pavblu ** — aflibercept-ayyh. Billing codes = Q5147.
    Pedmark IV solution — sodium thiosulfate. Billing codes = J0208.
    Pemetrexed — pemetrexed (multiple manufacturers). Billing codes = J9305, J9296, J9322, J9297, J9314, J9294.
    Breyanzi †† ‡ — lisocabtagene maraleucel. Billing codes = Q2054.
    Brineura — cerliponase alfa. Billing codes = J0567.
    Briumvi ** — ublituximab-xiiy. Billing codes = J2329.
    Byooviz ** — ranibizumab-nuna intravitreal solution. Billing codes = Q5124.
    Carvykti †† — ciltacabtagene autoleucel. Billing codes = Q2056.
    Casgevy †† — exagamglogene autotemcel. Billing codes = J3392.
    Cerezyme ** — imiglucerase. Billing codes = J1786.
    Cimerli * — ranibizumab-eqrn. Billing codes = Q5128.
    Cimzia ** — certolizumab pegol. Billing codes = J0717.
    Cinqair — reslizumab. Billing codes = J2786.
    Cinryze ** — C1 esterase inhibitor (human). Billing codes = J0598.
    Columvi — glofitamab-gxbm. Billing codes = J9286.
    Darzalex — daratumumab. Billing codes = J9145.
    Darzalex Faspro — daratumumab and hyaluronidase-fihj. Billing codes = J9144.
    Datroway — datopotamab deruxtecan. Billing codes = J9011.
    Dawnzera ** ‡ — donidalorsen. Billing codes = C9399, J3490.
    Daxxify — daxibotulinumtoxinA-lanm. Billing codes = J0589.
    Epogen ** ‡ — epoetin alfa. Billing codes = J0885.
    Epysqli IV ** — eculizumab-aagh. Billing codes = Q5151.
    Erbitux — cetuximab. Billing codes = J9055.
    Erwinase ‡ — crisantaspase. Billing codes = J9019.
    Euflexxa ** — sodium hyaluronate. Billing codes = J7323.
    Evenity ** — romosozumab-aqqg. Billing codes = (see claim submission guidance).
    Herceptin Hylecta — trastuzumab and hyaluronidase-oysk. Billing codes = J9356.
    Blood-clotting factors (examples): Nuwiq — simoctocog alfa. Billing codes = J7209; Obizur — antihemophilic factor (recombinant), porcine sequence. Billing codes = J7188; Profilnine — factor IX complex. Billing codes = J7194; Qfitlia ** ‡ — fitusiran. Billing codes = J7174; Rebinyn — Factor IX recombinant, GlycoPEGylated. Billing codes = J7203; Recombinate ‡ — antihemophilic factor [recombinant]. Billing codes = J7192; Rixubis — coagulation factor IX [recombinant]. Billing codes = J7200; Roctavian — valoctocogene roxaparvovec-rvox. Billing codes = J1412; SevenFact — coagulation factor VIIa (recombinant)-jncw; eptacog beta. Billing codes = J7212; Tretten — coagulation factor XIII A-subunit [recombinant]. Billing codes = J7181; Vonvendi — von Willebrand factor [recombinant]. Billing codes = J7179; Wilate — von Willebrand factor / coagulation factor VIII complex [human]. Billing codes = J7183; Xyntha / Xyntha Solofuse ‡ — antihemophilic factor [recombinant]. Billing codes = J7185.

    Billing Codes and NDC Requirements

    Examples of HCPCS/J-codes listedmixed
    Q2055Abecma — idecabtagene vicleucel (billing code as listed)
    J9264Abraxane — paclitaxel protein-bound (billing code as listed)
    J3262Actemra IV — tocilizumab (billing code as listed)
    Examples of HCPCS/CPT billing codes listedHCPCS
    J0585Botox — onabotulinumtoxinA
    Q2056Carvykti — ciltacabtagene autoleucel
    J0885Epogen — epoetin alfa
    Representative medication billing codesHCPCS | CPT
    J9356Herceptin Hylecta — trastuzumab and hyaluronidase-oysk
    J1559Hizentra — immune globulin
    J7321Hyalgan — sodium hyaluronate
    J1306Leqvio — inclisiran (billing code J1306 listed)
    Additional medication billing codesHCPCS | CPT
    J9350Lunsumio Velo — mosunetuzumab-axgb
    J9047Kyprolis — carfilzomib
    J2350Ocrevus — ocrelizumab
    Examples of HCPCS/J-codes listedHCPCSCovered
    J9177Padcev — enfortumab vedotin-ejfv
    J1304Qalsody — tofersen (billing code J1304)
    J9381Tzield — teplizumab-mzwv (billing code J9381)
    Representative HCPCS/CPT drug billing codes in this sectionHCPCS
    Q5115Truxima — rituximab-abbs (example billing code Q5115)
    J2323Tysabri — natalizumab (billing code J2323)
    J7686Tyvaso — treprostinil (inhaled) (billing code J7686)
    J3032Vyepti — eptinezumab-jjmr (billing code J3032)
    J9153Vyxeos — billing code (listed in section)
    J9223Zepzelca — lurbinectedin (billing code J9223)
    HCPCS/J-code list for blood-clotting factorsHCPCS | mixedCovered
    J7209Nuwiq — simoctocog alfa
    J7188Obizur — antihemophilic factor [recombinant], porcine sequence
    J7194Profilnine — factor IX complex
    J7174Qfitlia — fitusiran
    J7203Rebinyn — Coagulation Factor IX [Recombinant], GlycoPEGylated
    J7192Recombinate — antihemophilic factor [recombinant]
    J7200Rixubis — coagulation factor IX [recombinant]
    J1412Roctavian — valoctocogene roxaparvovec-rvox
    J7212SevenFact — coagulation factor VIIa (recombinant)-jncw; eptacog beta
    J7181Tretten — coagulation factor XIII A-subunit [recombinant]
    1–10 of 13
    1/2
    HCPCS NDC billing requirement
    RequirementAll shared HCPCS and not otherwise classified (NOC) codes must include a corresponding National Drug Code (NDC) on all claims.
    ScopeApplies to all listed medications and services using shared HCPCS/NOC codes across Humana MA plans referenced in this document.
    RationaleEnsures accurate drug identification and claim adjudication when HCPCS codes are shared or non‑specific.
    Related noteMarked in the list with symbol '‡' to indicate NDC requirement on claims.
    NDC requirement for shared HCPCS/NOC

    How to Request Prior Authorization and Required Provider Steps

    Prior Authorization

    How to request prior authorization — initiation pathways

    Except where noted, prior authorization for medications may be initiated in one of three ways: Online via CoverMyMeds (http://www.covermymeds.com/), by phone at 866-461-7273 (TTY: 711), Monday – Friday, 8 a.m. – 11 p.m. Eastern time, or by fax to 888-447-3430. For transplant-related preauthorization requests, submit via fax to 502-508-9300, by phone at 866-421-5663 (Mon–Fri, 7 a.m. – 7 p.m. Central), or by email to transplant@humana.com. Request forms are available on Humana's prior authorization for professionally administered drugs website.

    • Online: CoverMyMeds (http://www.covermymeds.com/)
    • Phone: 866-461-7273 (TTY: 711), Mon–Fri, 8 a.m.–11 p.m. ET
    • Fax: 888-447-3430 (request forms on Humana website)
    • Transplant submissions: fax 502-508-9300; phone 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. CT); email transplant@humana.com
    Documentation Required

    Definitions and Legend

    Prior authorization
    DefinitionPrior authorization is the process through which the healthcare provider is required to obtain advance approval from the plan as to whether an item or service will be covered.
    When requiredPrior authorization is required for medications and services listed in this document before they are provided or administered.
    How to initiateRequests may be submitted by phone, fax, or using the methods described in the provider instructions (see contact details in the document).
    Active course of treatment exception
    ExceptionNo prior authorization required for basic Medicare benefits during the first 90 days of a new member's enrollment for active courses of treatment that started prior to enrollment.
    Provider action
    Policy Summary
    PayerHumana
    PolicyPrior authorization and notification list — Humana Dual Fully Integrated Illinois
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionInitiate prior authorization via CoverMyMeds, by phone at 866-461-7273 (TTY: 711), or by fax to 888-447-3430 and include required patient, billing and clinical information.
    SourceLink
    On This Page
    Prior Authorization and Notification Coverage CriteriaBilling Codes and NDC RequirementsHow to Request Prior Authorization and Required Provider StepsDefinitions and Legend
    RequirementAll shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding NDC to be billed on all claims.
    NotationSymbol '‡' in the medication list indicates this NDC billing requirement.
    Submission impactProviders must include the NDC on claims to avoid adjudication issues or payment delays.
    ReferenceSee legend/notes for submission methods and additional preauthorization instructions where applicable.
    NDC billing requirement
    Billing ruleAll shared HCPCS and not otherwise classified codes require a corresponding NDC on claims.
    Legend symbol'‡' denotes the NDC billing requirement next to affected products in the list.
    Operational noteFailure to include the NDC may affect claim processing; follow Humana claims payment and coding guidance.
    Applies toIncludes blood‑clotting factor products and other medications flagged with '‡' throughout the document.

    Information required for prior authorization

    Submit the following information with a prior authorization request or notification. Including all relevant clinical documentation up front helps expedite determinations; Humana may request additional information if needed.

    • Patient name, date of birth, Humana member ID
    • Date of service or hospital admission
    • HCPCS code(s) and diagnosis codes (primary and secondary) — up to 6 diagnosis codes per request
    • Service location (e.g., telehealth, office, home, off-campus or on-campus outpatient hospital, ambulatory surgery center)
    • Tax Identification Number (TIN) and National Provider Identifier (NPI) for the facility where service is rendered and for the provider performing the service
    • Caller/requester name and phone number and attending provider phone number
    • Relevant clinical information and supporting documentation
    Prior Authorization

    Request preauthorization / provide notification — submission instructions

    Access the Humana fax forms to request preauthorization or provide notification for the medications listed on the prior authorization/notification list. Billing (HCPCS/J/C) codes are provided alongside each drug entry in the list. Some entries include special markers: * = new preauthorization requirement; † = new-to-market drug; ‡ = HCPCS shared/NOC code — requires corresponding NDC on claims; ** = step therapy required; †† = transplant-reviewed item.

    • Use the listed billing codes when submitting the request (HCPCS/J-codes are shown per drug)
    • For ‡ codes, include the corresponding NDC on all claims
    • For ** entries, follow step therapy requirements (Humana-preferred drug must be tried where applicable)
    • For †† items, follow Humana National Transplant Network submission pathways
    Denial Risk

    Submission notes and special processes

    Submission notes and special processes: some medications are newly subject to prior authorization or are new-to-market; shared HCPCS and NOC codes require corresponding NDCs on claims; step therapy markers indicate a required trial of a Humana-preferred agent as part of preauthorization. Preauthorization denials or failure to obtain required prior authorization may result in financial penalties to the practice and reduced benefits for the patient and services may be subject to retrospective medical necessity review.

    • * = New preauthorization requirement
    • † = New-to-market drug addition
    • ‡ = Shared HCPCS/NOC codes require corresponding NDC on claims
    • ** = Step therapy required through a Humana-preferred drug as part of preauthorization
    • Not obtaining prior authorization may lead to financial penalties and retrospective denials
    Note

    Prior authorization notes and contact

    Contact and legend notes: request forms are available on Humana's prior authorization for professionally administered drugs website. For questions about the list or submission process, use the phone and fax numbers above. For transplant-related questions or to submit transplant reviews, contact the Humana National Transplant Network (fax 502-508-9300; phone 866-421-5663; email transplant@humana.com).

    • Request forms available on Humana prior authorization for professionally administered drugs site
    • General prior authorization phone: 866-461-7273 (TTY: 711)
    • General prior authorization fax: 888-447-3430
    • Transplant review: fax 502-508-9300; phone 866-421-5663; email transplant@humana.com
    Prior Authorization

    How to request prior authorization — blood-clotting factors

    Blood-clotting factors require prior authorization. Use the Humana fax forms to submit requests or notifications and include the required clinical documentation and billing codes shown below. Shared/NOC HCPCS codes (‡) require the corresponding NDC on claims.

    • Advate — J7192 (antihemophilic factor, human recombinant) ‡
    • Adynovate — J7207 (antihemophilic factor [recombinant], PEGylated)
    • Afstyla — J7210 (antihemophilic factor [recombinant] single chain)
    • Alhemo ** — J7173 (concizumab-mtci)
    • Alphanate — J7186 (antihemophilic factor/von Willebrand factor complex [human])
    • AlphaNine SD — J7193 (coagulation factor IX [human])
    • Alprolix — J7201 (coagulation factor IX [recombinant])
    • Altuviiio — J7214 (efanesoctocog alfa)
    • Benefix ‡ — J7195 (coagulation factor IX [recombinant])
    • Beqvez — J1414 (fidanacogene elaparvovec-dzkt)
    • Coagadex — (see list)
    • Nuwiq — J7209 (simoctocog alfa)
    • Obizur — J7188 (antihemophilic factor [recombinant], porcine sequence)
    • Profilnine — J7194 (factor IX complex)
    • Qfitlia ** ‡ — J7174 (fitusiran)
    • Rebinyn — J7203 (Coagulation Factor IX [Recombinant], GlycoPEGylated)
    • Recombinate ‡ — J7192 (antihemophilic factor [recombinant])
    • Rixubis — J7200 (coagulation factor IX [recombinant])
    • Roctavian — J1412 (valoctocogene roxaparvovec-rvox)
    • SevenFact — J7212 (coagulation factor VIIa [recombinant]-jncw; eptacog beta)
    • Tretten — J7181 (coagulation factor XIII A-subunit [recombinant])
    • Vonvendi — J7179 (von Willebrand factor [recombinant])
    • Wilate — J7183 (von Willebrand factor / coagulation factor VIII complex [human])
    • Xyntha ‡ / Xyntha Solofuse ‡ — J7185 (antihemophilic factor [recombinant])
    Billing Rule

    Prior authorization required — blood-clotting factors

    Prior authorization is required for the blood-clotting factor products listed. Some products are marked for step therapy (**) or shared HCPCS/NOC (‡) — ensure step therapy requirements are met and include the corresponding NDC on claims for ‡ entries. Failure to include the NDC for shared/NOC HCPCS codes or to obtain required prior authorization may result in claim denials or retrospective review.

    • Prior authorization required for all listed blood-clotting factors
    • ** indicates step therapy required — document trials of Humana-preferred agents when applicable
    • ‡ indicates HCPCS shared/NOC — include corresponding NDC on claim submissions
    • Provide complete clinical documentation to avoid retrospective medical necessity review or financial penalties
    Step Therapy

    Step therapy and billing requirements

    Step therapy and billing requirements: entries marked ** require completion of step therapy through a Humana-preferred drug as part of the preauthorization process. Entries marked ‡ are shared or NOC HCPCS codes and require a corresponding NDC to be billed on all claims. Newly added prior authorization requirements (*) and new-to-market markers (†) appear throughout the list; follow the submission instructions and include requested documentation to support medical necessity.

    • ** = Step therapy required (document prior trials and responses)
    • ‡ = Shared HCPCS/NOC — include corresponding NDC on claims
    • * = New preauthorization requirement
    • † = New-to-market drug addition
    • For step therapy, include documentation of previous agent(s) tried, dates, dosages, and clinical response
    Include appropriate modifier or medical records evidence that member is in an active course of treatment to ensure correct claim payment.
    PurposePrevents disruption of care for ongoing treatment begun before plan enrollment.
    HCPCS/NDC billing requirement
    RequirementAll shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding NDC on claims (document symbol '‡').
    Where notedThe medication list uses '‡' to flag products that need an NDC submitted with the claim.
    ImpactApplies across the prior authorization list; ensures accurate identification when HCPCS codes are not unique to a single drug.
    Step therapy
    Step therapy indicator'**' indicates step therapy is required through a Humana‑preferred drug as part of preauthorization.
    Operational impactProviders must document trial and failure of preferred agents per Humana's Step Therapy Preferred Drug List when submitting preauthorization.
    ReferenceStep therapy requirements are noted alongside affected products in the medication list.
    Transplant preauthorization review
    Transplant reviewPreauthorization requests for transplant‑related therapies will be reviewed by the Humana National Transplant Network.
    Submission methodsRequests can be submitted by fax to 502‑508‑9300, by phone at 866‑421‑5663 (Mon–Fri 7 a.m.–7 p.m. CT), or by email to transplant@humana.com.
    ScopeApplies to items flagged in the list for transplant review (symbol '††').
    ‡ billing/NDC requirement
    Billing rule'‡' indicates shared HCPCS or not otherwise classified codes require a corresponding NDC on all claims.
    LocationThis symbol appears in the legend and beside affected products in the medication list.
    Provider actionInclude NDC on the claim form/bill when submitting reimbursement for flagged products.
    ** step therapy
    Step therapy marker'**' denotes that step therapy is required through a Humana‑preferred drug as part of preauthorization.
    ImplicationPreauthorizations for products marked '**' must document adherence to the step therapy pathway.
    ReferenceSee Humana's Medicare Part B Step Therapy Preferred Drug List for the preferred agents and criteria.
    †† transplant review
    Transplant review marker'††' indicates preauthorization requests will be reviewed by the Humana National Transplant Network.
    Contact optionsSubmit by fax 502‑508‑9300, phone 866‑421‑5663 (Mon–Fri 7 a.m.–7 p.m. CT), or email transplant@humana.com.
    ApplicabilityUsed next to transplant‑related therapies in the medication list to direct submission to the transplant network.
    ‡ (NDC requirement)
    NDC billing requirementAll shared HCPCS and not otherwise classified codes require a corresponding NDC on claims (denoted by '‡').
    Why it mattersEnsures claims include the specific drug NDC when a HCPCS code alone is insufficient to identify the product.
    Provider instructionInclude the NDC on the claim to prevent claim denials or payment delays for flagged items.
    ** (step therapy)
    Step therapy markProducts marked with '**' require step therapy through a Humana‑preferred drug as part of preauthorization.
    DocumentationPreauthorization submissions must show evidence of trials of preferred agents per Humana guidance.
    ReferenceStep therapy is noted in the legend and alongside affected drugs in the list.
    †† (transplant review)
    Transplant review processPreauthorization requests for certain products will be reviewed by the Humana National Transplant Network and should be submitted directly to that network.
    Submission channelsFax: 502‑508‑9300; Phone: 866‑421‑5663 (Mon–Fri 7 a.m.–7 p.m. CT); Email: transplant@humana.com.
    NoteThis routing applies to items flagged with '††' in the medication list.
    legend / special symbols
    Legend: '‡'Indicates shared HCPCS/NOC codes require a corresponding NDC on all claims.
    Legend: '**'Indicates step therapy required through a Humana‑preferred drug as part of preauthorization.
    Legend: '†' and '*''†' denotes new‑to‑market drug addition; '*' denotes new preauthorization requirement.
    Transplant legend: '††'Denotes items reviewed by the Humana National Transplant Network; contact details provided in the legend.
    * New preauthorization requirement
    Symbol '*'New preauthorization requirement (appears in legend and next to affected products).
    Provider actionCheck item‑level notes to determine if a product is newly added to preauthorization requirements.
    ContextUsed alongside other legend symbols to indicate status of the medication entry.
    † New-to-market drug addition
    Symbol '†'New‑to‑market drug addition (appears in the legend and next to applicable products).
    ImplicationMay require special review or newly established criteria; see product entry for details.
    ReferenceListed in the document legend with other special symbols.
    ‡ billing note
    Billing noteShared HCPCS or not otherwise classified codes require a corresponding NDC on all claims (denoted '‡').
    Where seenAppears in legend and beside multiple medication entries including blood‑clotting factors.
    Provider taskEnsure claims include the NDC for any product flagged with '‡'.
    ** step therapy note
    Step therapy noteStep therapy is required through a Humana‑preferred drug as part of preauthorization for products marked '**'.
    Documentation neededPreauthorization requests should include evidence of prior use of preferred agents as applicable.
    ReferenceStep therapy flag appears in the legend and next to affected drugs in the list.
    †† transplant review contact
    Transplant contactPreauthorization requests for certain items will be reviewed by the Humana National Transplant Network; submit by fax 502‑508‑9300, phone 866‑421‑5663 (Mon–Fri 7 a.m.–7 p.m. CT), or email transplant@humana.com.
    When to useUse these contact methods for products flagged with '††' in the medication list.
    PurposeRoutes transplant‑related preauthorization requests to the specialized transplant review team.